Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 6/20 | 0.34 |
| ▸ | CKS1B | P61024 | 2/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138207 | 0.92 | NAMPT (0.38) | SLC40A1ALDH1A1NAMPTTDP1 | |
| SCHEMBL4130108 | 0.87 | NFE2L2 (0.41) | SLC40A1ALDH1A1NAMPT | |
| SCHEMBL4132664 | 0.87 | NAMPT (0.38) | POLBALDH1A1NAMPTTBXAS1TDP1 | |
| SCHEMBL4126094 | 0.86 | NAMPT (0.35) | POLBALDH1A1NAMPTTBXAS1 | |
| SCHEMBL4130696 | 0.83 | SLC22A12 (0.36) | POLBGPBAR1ALDH1A1NAMPTTBXAS1 | |
| SCHEMBL4130745 | 0.81 | GPBAR1 (0.40) | SLC40A1GPBAR1ALDH1A1NAMPTCKS1B | |
| Fumaric Acid SCHEMBL3649699 | 0.81 | GPBAR1 (0.35) | POLBSLC40A1GPBAR1NAMPTCKS1B | |
| SCHEMBL4126636 | 0.81 | GAA (0.39) | ALDH1A1NAMPTTDP1 | |
| Fumaric Acid SCHEMBL3649706 | 0.81 | GPBAR1 (0.35) | POLBSLC40A1GPBAR1NAMPTCKS1B | |
| SCHEMBL3648437 | 0.81 | GPBAR1 (0.36) | SLC40A1GPBAR1CKS1BSKP2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | POLB 4579/4885SLC40A1 2890/4885GPBAR1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.